Dana-Farber Cancer Institute: Immunotherapy - Targeted Drug Combination Improves Survival in Advanced Kidney Cancer
February 15, 2021
February 15, 2021
BOSTON, Feb. 15 (TNSJou) -- The Dana-Farber Cancer Institute issued the following news release:
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.
The survival benefit demonstrates that an immune checkpoint inhibitor togeth . . .
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.
The survival benefit demonstrates that an immune checkpoint inhibitor togeth . . .